Join a Round Table Meeting: Humanized IgG Göttingen Minipigs – Future Perspectives

After the publication in Nature of the scientific article on the topic, the first Humanized IgG Göttingen Minipigs were commercialized in the beginning of October. The Humanized Minipigs have been genetically modified to carry a mini-repertoire of human genes for the immunoglobulin heavy chains y1 and 4 and the immunoglobulin light chain κ, making the them  less prone to developing an immune response to human antibodies and thereby open for the possibility to use minipigs as a non-rodent model for studies with therapeutic antibodies.

We will in this meeting provide you with key insights into the new possibilities that have opened up with this scientific breakthrough.

Note: There is a limited number of seats available, and they are offered on a first come – first serve basis.

Program

Speakers

Dr. Tatiana Flisikowska
Dr. Tatiana Flisikowska is Senior Scientist at the Chair of Livestock Biotechnology at the Technical University of Munich. She has many years of experience in the production and characterisation of genetically modified biomedical pig models, especially for cancer research and is first-author of the scientific article – A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies – published in Nature Biomedical Engineering, 22 September 2022.

Jerome Egli, PhD, ERT
Toxicology Project leader at Roche, mainly contributing to projects on large molecules for cancer immunotherapy. Jerome has a Bachelor in Biology from the University of Basel and graduated with a Master of Science in Toxicology, and obtained his PhD from the University of Basel in close collaboration with Roche where he characterized the Fc gamma receptors of minipigs in interaction with human IgG antibodies and did his Postdoctoral research at Roche on the impact of the mode of action of T cell-engagers on immunogenicity. Author of the scientific article – A humanized minipig model for the toxicological testing of therapeutic recombinant antibodies – published in Nature Biomedical Engineering, 22 September 2022.

Frederikke Lihme Egerod, PhD, ERT
Director at Genmab, providing strategic and scientific input on nonclinical toxicology programs within oncology from FIH enabling studies to BLA filing. Frederikke holds a PhD in Biomedicine from the University of Copenhagen and has industry experience from Novo Nordisk, Leo Pharma, Symphogen and Genmab in the development of pharmaceuticals and the nonclinical safety evaluation of both small molecules and biologics. Frederikke has led the safety assessments of several potential new medicines to enable FIH clinical studies.

Ellegaard Göttingen Minipigs A/S
International provider of Göttingen Minipigs of the highest health standards to biomedical research.

Scantox Group
Leading Nordic CRO for preclinical research. Furthermore, Mikkel Lykke Jensen is appointed by Dansk Industri as the industry expert in the Danish National Committee regulating the use of animals in science.

 The round table is hosted by Scantox Group and Ellegaard Göttingen Minipigs A/S